SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
{1} Adds Three Clinical-Stage Oncology Drug Candidates To Its Pipeline, Including A Novel, First-In-Class, Oral AKT-Inhibitor In Phase II